Gyre Therapeutics Files Definitive Proxy Statement
Ticker: GYRE · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: GYRE
TL;DR
Gyre Therapeutics (GYRE) filed its proxy statement for the June 4th meeting. Shareholders vote soon.
AI Summary
Gyre Therapeutics, Inc. (formerly Catalyst BioSciences, Inc.) is filing its definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 4, 2025. The company, located at 12770 High Bluff Drive, San Diego, CA, operates in the pharmaceutical preparations sector. This filing is a standard procedural document for shareholder voting.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, allowing them to make informed voting decisions on company matters.
Risk Assessment
Risk Level: low — This is a routine SEC filing (DEF 14A) that provides information for an upcoming shareholder meeting and does not contain new material financial or operational news.
Key Numbers
- 20250421 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250604 — Meeting Date (Date of the shareholder meeting for which the proxy statement is issued.)
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Registrant
- CATALYST BIOSCIENCES, INC. (company) — Former Company Name
- TARGACEPT INC (company) — Former Company Name
- 0001140361-25-014779 (dollar_amount) — Accession Number
- 20250421 (dollar_amount) — Filing Date
- 20250604 (dollar_amount) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The DEF 14A filing is a definitive proxy statement filed by Gyre Therapeutics, Inc. to provide shareholders with information regarding the annual meeting of stockholders and matters to be voted upon.
When is the shareholder meeting scheduled?
The shareholder meeting is scheduled for June 4, 2025.
What was Gyre Therapeutics, Inc. formerly known as?
Gyre Therapeutics, Inc. was formerly known as Catalyst BioSciences, Inc. and prior to that, Targacept Inc.
Where is Gyre Therapeutics, Inc. located?
Gyre Therapeutics, Inc. is located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 21, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding GYRE THERAPEUTICS, INC. (GYRE).